GHK-Cu, or glycyl-histidyl-lysine copper complex, was first identified in human plasma by Loren Pickart in the early 1970s during research on liver function. The observation that a fraction isolated from young human serum stimulated specific cellular processes in tissue samples set off several decades of investigational work into what was happening at the molecular level.
The copper atom is central to the peptide activity. GHK binds copper with high affinity, and the resulting complex interacts with cell surface receptors and extracellular matrix components in ways that differ from the free peptide alone. In cell culture studies, GHK-Cu has been shown to stimulate fibroblasts to produce collagen, specifically type I and type III collagen, which are the primary structural proteins in skin and connective tissue.
Beyond structural proteins, researchers have examined GHK-Cu effects on antioxidant enzyme systems. Several studies have reported upregulation of superoxide dismutase (SOD) and catalase activity in treated cells, both of which are key components of intracellular reactive oxygen species management. A 2015 paper by Pickart and colleagues published in the Journal of Aging Research documented changes in gene expression profiles consistent with antioxidant and anti-inflammatory activity across hundreds of genes in cultured cells treated with GHK.
Wound healing applications have also been studied extensively. Animal model research has demonstrated accelerated closure rates and improved tensile strength in wounds treated with GHK-Cu compared to controls. The proposed mechanism involves not only collagen production but also angiogenesis stimulation, which improves blood supply to healing tissue, and modulation of matrix metalloproteinases, enzymes that remodel the extracellular matrix.
It is important to note that while the in vitro and animal literature on GHK-Cu is substantial, human clinical data remains limited. The compound is sold by Vanguard Research Labs for qualified research purposes only and should not be interpreted as having established therapeutic benefit in humans based on current published evidence.